Pages that link to "Q35443048"
Jump to navigation
Jump to search
The following pages link to CROSS RESISTANCE AND COLLATERAL SENSITIVITY STUDIES IN CANCER CHEMOTHERAPY. (Q35443048):
Displaying 16 items.
- FOLIC ACID METABOLISM IN ANTIFOLIC-RESISTANT MUTANTS OF STREPTOCOCCUS FAECALIS (Q34540850) (← links)
- Cross-resistance and collateral susceptibility to antifolic antimalarial compounds (Q35642417) (← links)
- Mutagenic Studies of Folic Acid Antagonists (Q36464801) (← links)
- Experimental chemoimmunotherapy of cancer (Q39724416) (← links)
- Nucleotide Biosynthesis from Preformed Purines in Mammalian Cells: Regulatory Mechanisms and Biological Significance (Q39989444) (← links)
- Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells (Q41921173) (← links)
- Modification of in vivo methotrexate antitumor effect in L1210 leukemia by induced impairment of purine salvage (Q44145490) (← links)
- ON THE MORPHOLOGICAL EFFECT OF DIFFERENT CHEMOTHERAPEUTIC AGENTS ON DEGRANOL-SENSITIVE AND DEGRANOL-RESISTANT NK/LY ASCITES TUMOR (Q54712478) (← links)
- Taking advantage of drug resistance, a new approach in the war on cancer (Q57172217) (← links)
- Repurposing of Bromocriptine for Cancer Therapy (Q57817601) (← links)
- With great power comes great vulnerability (Q58130375) (← links)
- Individualized Tumor Therapy: Biomarkers and Possibilities for Targeted Therapy with Natural Products (Q58595085) (← links)
- Cytotoxicity of nimbolide towards multidrug-resistant tumor cells and hypersensitivity via cellular metabolic modulation (Q59800908) (← links)
- Uptake as a Determinant of Methotrexate Response in Mouse Leukemias (Q72592549) (← links)
- Biologic-Response Modifiers and Adjuvant Chemotherapy: Consideration of Selected Preclinical Investigations in Relation to Clinical Potential (Q72658105) (← links)
- Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors (Q90364090) (← links)